CLAIMS

1. A compound of formula (I):



(I)

or tautomer, pharmaceutically acceptable salt thereof, wherein:
A is aryl;
L is bond or absent;
R_1 and R_2 are hydrogen;
R_3 and R_4 are independently selected from the group consisting of hydrogen, deuterium, halogen, alkyl, alkoxy, haloalkyl, deuterated alkoxy, haloalkoxy, cycloalkyl, cycloalkylxoy, optionally the alkyl, alkoxy, haloalkyl, deuterated alkoxy, haloalkoxy, cycloalkyl, and cycloalkylxoy substituted with one or more substituents selected from deuterium, halogen, amino, cyano, hydroxy, alkyl, alkoxy, alkylthio, haloalkyl, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl;
two of R_5 together with the C atom to which they are attached form C_{4-6} cycloalkyl or C_{4-6} heterocyclyl, optionally the C_{4-6} cycloalkyl or C_{4-6} heterocyclyl substituted with one or more substituents selected from halogen, amino, cyano, hydroxy, alkyl, alkoxy, alkylalkoxy, alkoxyalkyl, alkylthio, haloalkyl and hydroxyalkyl;
R_6 is selected from the group consisting of amino, cyano, hydroxy, alkyl, alkoxy, alkylthio, haloalkyl, hydroxyalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, $–(CH_2)_rOR_8$,– $(CH_2)_rC(O)R_8$, -S(O)NHalkyl, $-SO_2$alkyl, $-C(O)NHSO_2$alkyl and $-SO_2NHC(O)$alkyl
R_7 is selected from the group consisting of hydrogen, alkyl, and hydroxyalkyl;
R_8 is selected from the group consisting of hydrogen, deuterium, halogen, amino, cyano, hydroxy, alkyl, alkoxy, alkylthio, haloalkyl and hydroxyalkyl;
r is 0, 1, 2 or 3;
t is 2 or 3;
m is 2; and
n is 1, or 2;
provided that if
R_1 and R_2 is hydrogen, R_3 is cyclopropyl or methoxy, R_4 is methyl, L is bond, R_6 is –COOH or $–COOCH_3$, R_7 is hydrogen or trifluoromethyl, A is phenyl, and n is 1, 2 or 3, R_5 is not hydrogen or ;
R_1 and R_2 is hydrogen, R_4 is methyl, L is bond, R_7 is hydrogen, A is phenyl, pyridine or thiazolyl, m is 1, and n is 2, R_5 is not hydrogen, amino, hydroxy, methyl, ethyl, methoxy, ethyoxyl, propoxy, methylol, ethoxyl, cyanomethyl and methylamino;
R_1 and R_2 is hydrogen, R_4 is methyl, L is bond, R_7 is hydrogen, A is phenyl, m is 2 or 3, and n is 2, R_5 is not hydrogen or methyl.

2. The compound of claim 1, or tautomer, pharmaceutically acceptable salt thereof, wherein A is  , or  .

3. The compound of claim 1, or tautomer, pharmaceutically acceptable salt thereof, wherein
(i) L is bond;
or (ii) R_1 and R_2 are hydrogen;
or (iii) R_3 and R_4 are independently selected from the group consisting of deuterium, halogen, C_{1-3} alkyl, C_{1-3} alkoxy, deuterated C_{1-3} alkoxy, C_{1-3} haloalkoxy, C_{3-6} cycloalkyl and C_{3-6} cycloalkyloxy;
or (iv) R_6 is -OMe, $-CH_2OH$, $-CH_2OCH_3$, $-CH_2F$, $-CF_2H$, $-CF_3$, –COOH, $-C(O)NHSO_2CH_3$, $-S(O)NHCH_3$, or 5-6membered heterocyclyl containing 1-3 of heteroatom selected from N, O and S, or 5-6 membered heteroaryl containing 1-3 of heteroatom selected from N, O and S.

4. The compound of claim 1, or tautomer, pharmaceutically acceptable salt thereof, wherein two of R_5 together with the C atom to which they are attached form C_{4-6} cycloalkyl optionally substituted with one or more substituents selected from halogen, amino, cyano, hydroxy, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} alkylC_{1-6} alkoxy, C_{1-6} alkoxyC_{1-6} alkyl, C_{1-6} alkylthio, C_{1-6} haloalkyl and C_{1-6} hydroxyalkyl.

5. The compound of claim 1, or tautomer, pharmaceutically acceptable salt thereof, wherein R_7 is hydrogen or C_{1-3} alkyl.

6. The compound of any one of claims 1 to 5, or tautomer, pharmaceutically acceptable salt thereof, wherein the compound is of formula (II-c):



(II-c) ,

wherein,

B is  ,optionally substituted with one or more substituents selected from halogen, amino, cyano, hydroxy, C_{1-3} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{1-3} alkoxy, C_{1-3} alkylC_{1-3} alkoxy, C_{1-3} alkoxyC_{1-3} alkyl, C_{1-3}alkylthio, C_{1-3} haloalkyl and C_{1-3} hydroxyalkyl.

7. The compound of claim 6, or tautomer, pharmaceutically acceptable salt thereof, wherein the compound is of formula (III-c):



(III-c)

wherein,

 is , or , optionally substituted with one or more substituents selected from halogen, amino, cyano, hydroxy, C_{1-3} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{1-3} alkoxy, C_{1-3} alkylC_{1-3} alkoxy, C_{1-3} alkoxyC_{1-3} alkyl, C_{1-3}alkylthio, C_{1-3} haloalkyl and C_{1-3} hydroxyalkyl.

8. The compound of claim 7, or tautomer, pharmaceutically acceptable salt thereof, wherein,

A is ;

 is , optionally substituted with one or more substituents selected from halogen, amino, cyano, hydroxy, C_{1-3} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{1-3} alkoxy, C_{1-3} alkylC_{1-3} alkoxy, C_{1-3} alkoxyC_{1-3} alkyl, C_{1-3}alkylthio, C_{1-3} haloalkyl and C_{1-3} hydroxyalkyl;

R_6 is –COOH or -S(O)NHCH$_3$.

9. The compound of any one of claims 1 to 5, or tautomer, pharmaceutically acceptable salt thereof, wherein the compound is of formula (V-b):



(V-b)

M is CR_cR_d;

R_c and R_d are independently selected from halogen, hydrogen or C_{1-3} alkyl;

R_3 and R_4 are independently selected from C_{1-3} alkyl, C_{1-3} alkoxy or C_{3-6} cycloalkyl;

R_6 is –COOH, -C(O)NHSO$_2$CH$_3$ or -S(O)NHCH$_3$;

R_7 is hydrogen, C_{1-3} alkyl or C_{1-3} hydroxyalkyl;

R_{10} is C_{1-3} alkyl or C_{1-3} haloalkyl;
n is 1 or 2;
s is 1, and
t is 1.

10. The compound of any one of claims 1 to 5, or tautomer, pharmaceutically acceptable salt thereof, wherein the compound is of formula (VI):



(VI)

R_3 and R_4 are independently selected from deuterium, halogen, C_{1-3} alkyl, C_{1-3} alkoxy, C_{3-6} cycloalkyl, C_{3-6} cycloalkyloxy, deuterated C_{1-3} alkoxy, C_{1-3} haloalkoxy and C_{3-6} cycloalkylC_{1-3} alkoxy;

R_6 is –COOH, -C(O)$NHSO_2CH_3$, -S(O)$NHCH_3$, 

or 

;
R_7 is hydrogen, C_{1-3} alkyl or C_{1-3} hydroxyalkyl;
R_{10} is C_{1-3} alkyl or C_{1-3} haloalkyl;
each of R_c and R_d is independently selected from halogen, hydrogen, C_{1-3} alkyl and C_{1-3} haloalkyl.

11. The compound of any one of claims 1 to 5 or claims 9 to 10, or tautomer, pharmaceutically acceptable salt thereof, wherein the compound is of formula (VI-a):



(VI-a) .

12. The compound of claim 11, or tautomer, pharmaceutically acceptable salt thereof, wherein:
R_3 and R_4 are independently selected from deuterium, halogen, C_{1-3} alkyl, C_{1-3} alkoxy, C_{3-6} cycloalkyl;
R_6 is –COOH, -C(O)$NHSO_2CH_3$, -S(O)$NHCH_3$;
R_7 is hydrogen, C_{1-3} alkyl or C_{1-3} hydroxyalkyl;
R_{10} is C_{1-3} alkyl or C_{1-3} haloalkyl;
each of R_c and R_d is independently selected from halogen, hydrogen, C_{1-3} alkyl and C_{1-3} haloalkyl.

13. The compound of claim 11, or tautomer, pharmaceutically acceptable salt thereof, wherein the compound is of formula (VI-b):



（ **VI-b**）

R_3 and R_4 are independently selected from deuterium, halogen, C_{1-3} alkyl, C_{1-3} alkoxy, cyclopropyl, cyclobutyl;

R_6 is –COOH, -C(O)NHSO$_2$CH$_3$, -S(O)NHCH$_3$;

R_7 is hydrogen, C_{1-3} alkyl or C_{1-3} hydroxyalkyl;

R_{10} is C_{1-3} alkyl or C_{1-3} haloalkyl, wherein the haloalkyl group contains at least two halogen atoms selected from F;

each of R_c and R_d is independently selected from halogen, C_{1-3} alkyl and C_{1-3} haloalkyl.

14. The compound of claim 1, or tautomer, pharmaceutically acceptable salt thereof, wherein the compound selected from the following structure:





and .

15. A pharmaceutical composition comprising a therapeutically effective amount of the compound of any one of claims 1 to 14, or tautomer, pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

16. The pharmaceutical composition of claim 15, wherein, (i) the amount of the compound, tautomer, cis- or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or pharmaceutically acceptable salts thereof, is 0.1%~95% by weight of free base; or (ii) the pharmaceutical composition is in the form of tablet, capsule, liquid or injection; or (iii) the pharmaceutical composition is in an immediate release dosage or sustained release dosage;
or (iv) the pharmaceutical composition comprises at least one pharmaceutically acceptable excipients, carries, or vehicles selected from the group consisting of fillers, disintegrants, glidants, lubricants or diluents;
or (v) the unit dosage of the compound, tautomer, cis- or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or pharmaceutically acceptable salts thereof, is 1-1000mg by weight of free base.

17. The pharmaceutical composition of any one of claims 15-16, wherein: (i) the amount of the compound, tautomer, cis- or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or pharmaceutically acceptable salts thereof, is 1%~60% by weight of free base; or
(ii) the pharmaceutical composition is in the form of tablet, capsule, liquid or injection;

or (iii) the pharmaceutical composition is in an immediate release dosage or sustained release dosage;
or (iv) the pharmaceutical composition comprises at least one pharmaceutically acceptable excipients, carries, or vehicles selected from the group consisting of fillers, disintegrants, glidants, lubricants or diluents;
or (v) the unit dosage of the compound, tautomer, cis- or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or pharmaceutically acceptable salts thereof, is 1-500mg by weight of free base.

18. The pharmaceutical composition of any one of claims 15-17, wherein: (i) the amount of the compound, tautomer, cis- or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or pharmaceutically acceptable salts thereof, is 15%~40% by weight of free base; or
(ii) the pharmaceutical composition is in the form of tablet, capsule, liquid or injection;
or (iii) the pharmaceutical composition is in an immediate release dosage or sustained release dosage;
or (iv) the pharmaceutical composition comprises at least one pharmaceutically acceptable excipients, carries, or vehicles selected from the group consisting of fillers, disintegrants, glidants, lubricants or diluents;
or (v) the unit dosage of the compound, tautomer, cis- or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or pharmaceutically acceptable salts thereof, is 3-300mg by weight of free base.

19. The pharmaceutical composition of any one of claims 15-18, wherein: (i) the amount of the compound, tautomer, cis- or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or pharmaceutically acceptable salts thereof, is 20%~25% by weight of free base; or
(ii) the pharmaceutical composition is in the form of tablet, capsule, liquid or injection;
or (iii) the pharmaceutical composition is in an immediate release dosage or sustained release dosage;
or (iv) the pharmaceutical composition comprises at least one pharmaceutically acceptable excipients, carries, or vehicles selected from the group consisting of fillers, disintegrants, glidants, lubricants or diluents;
or (v) the unit dosage of the compound, tautomer, cis- or trans-isomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or pharmaceutically acceptable salts thereof, is 1mg, 2mg, 3mg, 5mg, 10mg, 20mg, 40mg, 50mg, 60mg, 80mg, 100mg, 200mg, 300mg, 400mg or 500mg by weight of free base.

20. The use of the compound according to any one of claims 1-14 or the pharmaceutical composition of any one of claims 15-19, in which the disease or disorder is selected from the group consisting of age-related macular degeneration, geographic atrophy, diabetic retinopathy, uveitis, retinitis pigmentosa, macular edema, Behcet's uveitis, multifocal choroiditis, Vogt-Koyangi-Harada syndrome, imtermediate uveitis, birdshot retino-chorioditis, sympathetic ophthalmia, ocular dicatricial pemphigoid, ocular pemphigus, nonartertic ischemic optic neuropathy, post-operative inflammation, retinal vein occlusion, neurological disorders, multiple sclerosis, stroke, Guillain Barre Syndrome, traumatic brain injury, Parkinson's disease, hemodialysis complications, hyperacute allograft rejection, xenograft rejection, interleukin-2 induced toxicity during IL-2 therapy, inflammatory disorders, inflammation of autoimmune diseases, Crohn's disease, adult respiratory distress syndrome, myocarditis, post- ischemic reperfusion conditions, myocardial infarction, balloon

angioplasty, post-pump syndrome in cardiopulmonary bypass or renal bypass, atherosclerosis, hemodialysis, renal ischemia, mesenteric artery reperfusion after aortic reconstruction, infectious disease or sepsis, immune complex disorders and autoimmune diseases, rheumatoid arthritis, systemic lupus erythematosus , SLE nephritis, proliferative nephritis, liver fibrosis, hemolytic anemia, myasthenia gravis, tissue regeneration, neural regeneration, dyspnea, hemoptysis, ARDS, asthma, chronic obstructive pulmonary disease, emphysema, pulmonary embolisms and infarcts, pneumonia, fibrogenic dust diseases, pulmonary fibrosis, asthma, allergy, bronchoconstriction, hypersensitivity pneumonitis, parasitic diseases, Goodpasture's Syndrome, pulmonary vasculitis, Pauci-immune vasculitis, immune complex-associated inflammation, antiphospholipid syndrome, membrane nephropathy, paroxysmal sleep hemoglobin urine, IgA nephropathy, glomerulonephritis and obesity.